VRDN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Viridian Therapeutics Inc (VRDN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive analyst ratings and a promising pipeline, the technical indicators show no clear bullish signals, and the financial performance is concerning due to significant net income and EPS declines. The lack of recent news or strong trading trends further supports a cautious approach.
The MACD is negative and contracting (-0.373), RSI is at 24.92 (neutral zone), and moving averages are converging, indicating no clear trend. The current price of $27.4 is near the S1 support level of $27.74, but no strong reversal signals are evident.
Analyst ratings are consistently positive, with price targets ranging from $41 to $50, reflecting confidence in the company's pipeline, particularly veligrotug for thyroid eye disease. Revenue growth in Q3 2025 was significant (up 81,958.14% YoY).
Net income dropped significantly (-54.88% YoY), and EPS declined (-63.48% YoY). The lack of recent news or significant hedge fund/insider activity suggests limited immediate catalysts. Technical indicators and options sentiment are not supportive of a bullish outlook.
In Q3 2025, revenue increased dramatically to $70.57M, but net income dropped to -$34.6M, and EPS fell to -0.42. Gross margin remained stable at 100%. While revenue growth is impressive, profitability remains a concern.
Analysts are optimistic, with multiple 'Buy' or 'Outperform' ratings and price targets ranging from $41 to $50. Analysts highlight the potential of veligrotug in thyroid eye disease and the company's strong pipeline.
